Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction

Phase 4 Completed 1012 enrolled Viatris Inc.

RandomizedParallel-groupQuadruple-blindPrevention

Summary

Administration of eplerenone within 24 hours of onset of symptoms of myocardial infarction, in patients without heart failure, reduces cardiovascular mortality / morbidity.

Timeline

Start: 2010-09
Primary completion: 2012-10
Completion: 2012-10

Outcome

Met primary endpoint

paper the primary endpoint occurred in 92 patients (18.2%) in the eplerenone group and in 149 patients (29.4%) in the placebo group PMID 24780614 ↗

registry Eplerenone Plus Standard of Care vs Placebo Plus Standard of Care; p < 0.0001; Cox Proportional Hazard 0.581 (95% CI 0.446 to 0.756) NCT01176968 ↗

paper It reduced the primary endpoint over a mean 13 months follow-up mostly because of significantly lower BNP/NT-proBNP levels. PMID 24780614 ↗

Publications

Montalescot G, Pitt B, Lopez de Sa E, Hamm CW, Flather M, Verheugt F, Shi H, Turgonyi E, Orri M, Vincent J, Zannad F; REMINDER Investigators; REMINDER Investigators. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study. Eur Heart J. 2014 Sep 7;35(34):2295-302. doi: 10.1093/eurheartj/ehu164. Epub 2014 Apr 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Eplerenone	Unknown	50 mg	—